Expression of Programmed Death-Ligand 1 by Human Colonic CD90+ Stromal Cells Differs Betweem Ulcerative Colitis and Crohn's Disease and Determines Their Capacity to Suppress Th1 Cells

被引:53
作者
Beswick, Ellen J. [1 ]
Grim, Carl [2 ]
Singh, Abinav [2 ]
Aguirre, Jose E. [2 ]
Tafoya, Marissa [3 ]
Qiu, Suimin [4 ]
Rogler, Gerhard [5 ]
McKee, Rohini [6 ]
Samedi, Von [3 ]
Ma, Thomas Y. [7 ]
Reyes, Victor E. [8 ,9 ]
Powell, Don W. [2 ]
Pinchuk, Irina V. [2 ,8 ]
机构
[1] Univ New Mexico, Dept Mol Genet & Microbiol, Albuquerque, NM 87131 USA
[2] Univ Texas Med Branch, Dept Internal Med, Galveston, TX 77555 USA
[3] Univ New Mexico, Dept Pathol, Albuquerque, NM 87131 USA
[4] Univ Texas Med Branch, Dept Pathol, Galveston, TX 77555 USA
[5] Univ Hosp Zurich, Dept Gastroenterol & Hepatol, Zurich, Switzerland
[6] Univ New Mexico, Dept Surg, Albuquerque, NM 87131 USA
[7] Univ New Mexico, Div Gastroenterol & Hepatol, Dept Internal Med, Albuquerque, NM 87131 USA
[8] Univ Texas Med Branch, Dept Microbiol & Immunol, Galveston, TX 77555 USA
[9] Univ Texas Med Branch, Dept Pediat, Galveston, TX 77555 USA
关键词
myofibroblasts; fibroblasts; programmed death-ligand 1; PD-L2; ulcerative colitis; Crohn's disease; inflammatory bowel diseases; Th1; cells; INFLAMMATORY-BOWEL-DISEASE; IMMUNE CHECKPOINT INHIBITORS; REGULATORY T-CELLS; LAMINA PROPRIA; STEM-CELL; PROINFLAMMATORY CYTOKINES; INTESTINAL MYOFIBROBLASTS; EPITHELIAL-CELLS; PD-1; PATHWAY;
D O I
10.3389/fimmu.2018.01125
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background and aims: The role of programmed cell death protein 1 (PD-1) and its ligands in the dysregulation of T helper immune responses observed in the inflammatory bowel disease (IBD) is unclear. Recently, a novel concept emerged that CD90(+) colonic (myo)fibroblasts (CMFs), also known as stromal cells, act as immunosuppressors, and are among the key regulators of acute and chronic inflammation. The objective of this study was to determine if the level of the PD-1 ligands is changed in the IBD inflamed colonic mucosa and to test the hypothesis that changes in IBD-CMF-mediated PD-1 ligand-linked immunosuppression is a mechanism promoting the dysregulation of Th1 cell responses. Methods: Tissues and cells derived from Crohn's disease (CD), ulcerative colitis (UC), and healthy individuals (N) were studied in situ, ex vivo, and in culture. Results: A significant increase in programmed death-ligand 1 (PD-L1) was observed in the inflamed UC colonic mucosa when compared to the non-inflamed matched tissue samples, CD, and healthy controls. UC-CMFs were among the major populations in the colonic mucosa contributing to the enhanced PD-L1 expression. In contrast, PD-L1 expression was decreased in CD-CMFs. When compared to CD-CMFs and N-CMFs, UC-CMFs demonstrated stronger suppression of IL-2, Th1 transcriptional factor Tbet, and IFN-gamma expression by CD3/CD28-activated CD4(+) T cells, and this process was PD-L1 dependent. Similar observations were made when differentiated Th1 cells were cocultured with UC-CMFs. In contrast, CD-CMFs showed reduced capacity to suppress Th1 cell activity and addition of recombinant PD-L1 Fc to CD-CMF: T cell cocultures partially restored the suppression of the Th1 type responses. Conclusion: We present evidence showing that increased PD-L1 expression suppresses Th1 cell activity in UC. In contrast, loss of PD-L1 expression observed in CD contributes to the persistence of the Th1 inflammatory milieu in CD. Our data suggest that dysregulation of the Th1 responses in the inflamed colonic mucosa of IBD patients is promoted by the alterations in PD-L1 expression in the mucosal mesenchymal stromal cell compartment.
引用
收藏
页数:15
相关论文
共 58 条
[1]   PD-L1 and PD-L2 modulate airway inflammation and iNKT-cell-dependent airway hyperreactivity in opposing directions [J].
Akbari, O. ;
Stock, P. ;
Singh, A. K. ;
Lombardi, V. ;
Lee, W-L ;
Freeman, G. J. ;
Sharpe, A. H. ;
Umetsu, D. T. ;
DeKruyff, R. H. .
MUCOSAL IMMUNOLOGY, 2010, 3 (01) :81-91
[2]   Bone marrow mesenchymal progenitor cells inhibit lymphocyte proliferation by activation of the programmed death 1 pathway [J].
Augello, A ;
Tasso, R ;
Negrini, SM ;
Amateis, A ;
Indiveri, F ;
Cancedda, R ;
Pennesi, G .
EUROPEAN JOURNAL OF IMMUNOLOGY, 2005, 35 (05) :1482-1490
[3]   Exaggerated inflammatory response of primary human myeloid dendritic cells to lipopolysaccharide in patients with inflammatory bowel disease [J].
Baumgart, D. C. ;
Thomas, S. ;
Przesdzing, I. ;
Metzke, D. ;
Bielecki, C. ;
Lehmann, S. M. ;
Lehnardt, S. ;
Doerffel, Y. ;
Sturm, A. ;
Scheffold, A. ;
Schmitz, J. ;
Radbruch, A. .
CLINICAL AND EXPERIMENTAL IMMUNOLOGY, 2009, 157 (03) :423-436
[4]  
Bertha M, 2017, ACG CASE REP J, V4, DOI 10.14309/crj.2017.112
[5]   Expression of the programmed death ligand 1, b7-h1,on gastric epithelial cells after Helicobacter pylori exposure promotes development of CD4+ CD25+ FoxP3+ regulatory T cells [J].
Beswick, Ellen J. ;
Pinchuk, Irina V. ;
Das, Sournita ;
Powell, Don W. ;
Reyes, Victor E. .
INFECTION AND IMMUNITY, 2007, 75 (09) :4334-4341
[6]   TLR4 Activation Enhances the PD-L1-Mediated Tolerogenic Capacity of Colonic CD90+ Stromal Cells [J].
Beswick, Ellen J. ;
Johnson, Jameel R. ;
Saada, Jamal I. ;
Humen, Martin ;
House, Jenifer ;
Dann, Sara ;
Qiu, Suimin ;
Brasier, Allan R. ;
Powell, Don W. ;
Reyes, Victor E. ;
Pinchuk, Irina V. .
JOURNAL OF IMMUNOLOGY, 2014, 193 (05) :2218-2229
[7]   Nivolumab: targeting PD-1 to bolster antitumor immunity [J].
Brahmer, Julie R. ;
Hammers, Hans ;
Lipson, Evan J. .
FUTURE ONCOLOGY, 2015, 11 (09) :1307-1326
[8]   Safety and Activity of Anti-PD-L1 Antibody in Patients with Advanced Cancer [J].
Brahmer, Julie R. ;
Tykodi, Scott S. ;
Chow, Laura Q. M. ;
Hwu, Wen-Jen ;
Topalian, Suzanne L. ;
Hwu, Patrick ;
Drake, Charles G. ;
Camacho, Luis H. ;
Kauh, John ;
Odunsi, Kunle ;
Pitot, Henry C. ;
Hamid, Omid ;
Bhatia, Shailender ;
Martins, Renato ;
Eaton, Keith ;
Chen, Shuming ;
Salay, Theresa M. ;
Alaparthy, Suresh ;
Grosso, Joseph F. ;
Korman, Alan J. ;
Parker, Susan M. ;
Agrawal, Shruti ;
Goldberg, Stacie M. ;
Pardoll, Drew M. ;
Gupta, Ashok ;
Wigginton, Jon M. .
NEW ENGLAND JOURNAL OF MEDICINE, 2012, 366 (26) :2455-2465
[9]   Imbalances of CD4+ T-cell subgroups in Crohn's disease and their relationship with disease activity and prognosis [J].
Chao, Kang ;
Zhang, Shenghong ;
Yao, Jiayan ;
He, Yao ;
Chen, Baili ;
Zeng, Zhirong ;
Zhong, Bihui ;
Chen, Minhu .
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2014, 29 (10) :1808-1814
[10]   Gastrointestinal and Hepatic Complications of Immune Checkpoint Inhibitors [J].
Cramer P. ;
Bresalier R.S. .
Current Gastroenterology Reports, 2017, 19 (1)